Abstract

The interaction between captopril, an inhibitor of angiotensin converting enzyme and human serum albumin, a principal plasma protein in the liver has been investigated in vitro under a simulated physiological condition by UV-vis spectrophotometry and fluorescence spectrometry. The intrinsic fluorescence intensity of human serum albumin was strongly quenched by captopril. The binding constants and the number of binding sites can be calculated from the data obtained from fluorescence quenching experiments. The negative value of ΔG0 reveals that the binding process is a spontaneous process. According to the van’t Hoff equation, the standard enthalpy change (ΔH0) and standard entropy change (ΔS0) for the reaction were calculated to be 35.98 KJ●mol-1 and 221.25 J●mol-1 K. It indicated that the hydrophobic interactions play a main role in the binding of captopril to human serum albumin. In addition, the distance between captopril (acceptor) and tryptophan residues of human serum albumin (donor) was estimated to be 1.05 nm according to the Förster’s resonance energy transfer theory. The results obtained herein will be of biological significance in pharmacology and clinical medicine.

Highlights

  • The results obtained will be of biological significance in pharmacology and clinical medicine

  • 2.369 × The distance R < 8 nm [37] between donor and acceptor indicates that the energy transfer from Human serum albumin (HSA) to captopril occurred with high possibility

  • The interaction between captopril and HSA has been investigated by using fluorescence and ultraviolet (UV) absorption spectra in vitro under a simulated physiological condition in this work

Read more

Summary

Introduction

As an inhibitor of angiotensin converting enzyme (ACEI) with a short duration of action [1], it is a drug with a number of cellular actions and clinical applications, and it extensively used for treatment of chronic heart failure and hypertention [2] for it can catalyze the conversion of angiotensin I to angiotensin II. The drug stimulates prostaglandin production and release IL-2 production [4], and possesses immunosuppressant activity. It possesses inhibiting effects on hypertrophy and remodeling of myocardium without interference with the metabolism of fatty acid, and can improve the patients’ quality of life [5, 6]. Some clinical reports have showed that captopril can decrease the frequency and grade of ventricular ectopy in patients with heart failure or cardiac infarction

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call